IL163550A0 - Formulations of atorvastatin stabilized with alkali metal additions - Google Patents
Formulations of atorvastatin stabilized with alkali metal additionsInfo
- Publication number
- IL163550A0 IL163550A0 IL16355003A IL16355003A IL163550A0 IL 163550 A0 IL163550 A0 IL 163550A0 IL 16355003 A IL16355003 A IL 16355003A IL 16355003 A IL16355003 A IL 16355003A IL 163550 A0 IL163550 A0 IL 163550A0
- Authority
- IL
- Israel
- Prior art keywords
- atorvastatin
- formulations
- stabilized
- alkali metal
- metal additions
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title 1
- 238000007792 addition Methods 0.000 title 1
- 229910052783 alkali metal Inorganic materials 0.000 title 1
- 150000001340 alkali metals Chemical class 0.000 title 1
- 229960005370 atorvastatin Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN112DE2002 | 2002-02-14 | ||
| PCT/IB2003/000505 WO2003068191A1 (fr) | 2002-02-14 | 2003-02-14 | Formulations d'atorvastatine stabilisee avec des adjonctions de metaux alcalins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL163550A0 true IL163550A0 (en) | 2005-12-18 |
Family
ID=27620520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16355003A IL163550A0 (en) | 2002-02-14 | 2003-02-14 | Formulations of atorvastatin stabilized with alkali metal additions |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20030175338A1 (fr) |
| EP (1) | EP1336405A1 (fr) |
| JP (1) | JP2005522444A (fr) |
| KR (1) | KR20040101229A (fr) |
| CN (1) | CN1642526A (fr) |
| AP (1) | AP2004003112A0 (fr) |
| AR (1) | AR038839A1 (fr) |
| AU (1) | AU2003245736A1 (fr) |
| BR (1) | BR0307720A (fr) |
| CA (1) | CA2475722A1 (fr) |
| CO (1) | CO5600997A2 (fr) |
| EA (1) | EA200401059A1 (fr) |
| EC (1) | ECSP045235A (fr) |
| HR (1) | HRP20040829A2 (fr) |
| IL (1) | IL163550A0 (fr) |
| IS (1) | IS7404A (fr) |
| MX (1) | MXPA04007905A (fr) |
| NO (1) | NO20043790L (fr) |
| OA (1) | OA12777A (fr) |
| PE (1) | PE20030935A1 (fr) |
| PL (1) | PL371337A1 (fr) |
| WO (1) | WO2003068191A1 (fr) |
| ZA (1) | ZA200406970B (fr) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002057229A1 (fr) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE) |
| US7361772B2 (en) * | 2001-08-16 | 2008-04-22 | Biocon Limited | Process for the production of atorvastatin calcium |
| ATE452871T1 (de) | 2002-03-18 | 2010-01-15 | Biocon Ltd | Amorphe hmg-coa-reduktase-inhibitoren mit gewünschter teilchengrösse |
| US7179942B2 (en) | 2002-07-05 | 2007-02-20 | Bicon Limited | Halo-substituted active methylene compounds |
| AU2003231926A1 (en) | 2003-04-22 | 2004-11-19 | Biocon Limited | NOVEL PROCESS FOR STEREOSELECTIVE REDUCTION OF ss-KETOESTERS |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| ATE381322T1 (de) * | 2003-08-05 | 2008-01-15 | Zentiva As | Verfahren zur stabilisierung von atorvastatin |
| US7557238B2 (en) | 2003-09-18 | 2009-07-07 | Biocon Limited | Process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate |
| US20090042979A1 (en) * | 2004-08-06 | 2009-02-12 | Transform Pharmaceuticals Inc. | Novel Statin Pharmaceutical Compositions and Related Methods of Treatment |
| WO2006017698A2 (fr) * | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Nouvelles compositions pharmaceutiques a base de statines et methodes de traitement associees |
| JP2008516890A (ja) * | 2004-08-06 | 2008-05-22 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | 新規なフェノフィブラート製剤および関連治療方法 |
| EP1793815A4 (fr) | 2004-09-30 | 2010-12-29 | Reddys Lab Ltd Dr | Atorvastatine calcique amorphe |
| BRPI0519996A2 (pt) * | 2004-10-28 | 2009-04-07 | Warner Lambert Co | processo para formar atorvastatina amorfa |
| AU2005305460B2 (en) * | 2004-11-22 | 2011-04-21 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
| EP1819319A1 (fr) * | 2004-12-02 | 2007-08-22 | Warner-Lambert Company LLC | Compositions pharmaceutiques d'atorvastatine amorphe et leur procede de preparation |
| ES2263370B1 (es) * | 2005-02-16 | 2007-12-01 | Ercros Industrial, S.A. | Atorvastatina calcica amorfa estabilizada y procedimiento para su obtencion. |
| WO2006123358A2 (fr) * | 2005-02-22 | 2006-11-23 | Sun Pharmaceutical Industries Limited | Composition pharmaceutique orale stable |
| US20100222405A1 (en) * | 2005-05-03 | 2010-09-02 | Yatendar Kumar | Magnesium salts of hmg-coa reductase inhibitors |
| US20070004671A1 (en) * | 2005-05-20 | 2007-01-04 | Agarwal Sudeep K | Stable desloratadine compositions |
| WO2007004236A2 (fr) * | 2005-07-04 | 2007-01-11 | Ramu Krishnan | Medicament ou composes pharmaceutiques ameliores et preparation associee |
| US7772277B2 (en) | 2005-08-04 | 2010-08-10 | Transform Pharmaceuticals, Inc. | Formulations comprising fenofibrate and a statin, and related methods of treatment |
| AU2006313009B2 (en) * | 2005-11-10 | 2013-10-24 | Alphapharm Pty Ltd | Process to control particle size |
| WO2007053904A1 (fr) | 2005-11-10 | 2007-05-18 | Alphapharm Pty Ltd | Processus de regulation de la dimension de particule |
| DE602006014193D1 (de) | 2005-11-21 | 2010-06-17 | Warner Lambert Co | Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure-magnesium |
| WO2007061849A2 (fr) * | 2005-11-23 | 2007-05-31 | Merck & Co., Inc. | Procede de generation de solide amorphe pour agents pharmaceutiques insolubles dans l'eau |
| US20100168201A1 (en) * | 2005-11-29 | 2010-07-01 | Biocan Limited | Polymorphs of [R-(R*, R*) ]-2-(4-Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid Magnesium Salt (2:1) |
| EP1810667A1 (fr) * | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Composition pharmaceutique contenant de l'atorvastatin amorphé |
| US20070202159A1 (en) * | 2006-02-02 | 2007-08-30 | Mathur Rajeev S | Pharmaceutical composition comprising stabilized statin particles |
| US7772273B2 (en) * | 2006-02-10 | 2010-08-10 | Lifecycle Pharma A/S | Stabilized atorvastatin |
| WO2007099552A2 (fr) * | 2006-03-02 | 2007-09-07 | Matrix Labaratories Ltd | Nouvelle forme cristalline d'atorvastatine hémi-magnésium |
| HU227696B1 (en) * | 2006-04-13 | 2011-12-28 | Egyt Gyogyszervegyeszeti Gyar | Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it |
| SI22255A (sl) * | 2006-04-14 | 2007-10-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah |
| JP2009536638A (ja) * | 2006-05-11 | 2009-10-15 | バイオコン リミテッド | アトルバスタチンマグネシウムの結晶性形状ｂ４及びその方法 |
| US20080038332A1 (en) * | 2006-08-10 | 2008-02-14 | Cai Gu Huang | Stable pharmaceutical formulation comprising atorvastatin calcium |
| HU227610B1 (en) * | 2006-09-18 | 2011-09-28 | Richter Gedeon Nyrt | Pharmaceutical compositions containing rosuvastatin potassium |
| EP2081554A2 (fr) * | 2006-09-27 | 2009-07-29 | Dr. Reddy's Laboratories Ltd. | Compositions pharmaceutiques d'atorvastatine |
| EP2114404A4 (fr) * | 2006-12-21 | 2010-03-03 | Alphapharm Pty Ltd | Composé et composition pharmaceutiques |
| IS8587A (is) * | 2006-12-27 | 2008-06-28 | Actavis Group Hf. | Atorvastatin lyfjasamsetning |
| CN101224205B (zh) * | 2007-01-20 | 2010-11-17 | 石药集团中奇制药技术（石家庄）有限公司 | 一种阿托伐他汀和左旋氨氯地平的组合物及其制备方法 |
| IS8607A (is) * | 2007-02-09 | 2008-08-10 | Actavis Group Hf. | Stöðugar atorvastatin samsetningar |
| CZ300047B6 (cs) * | 2007-03-02 | 2009-01-21 | Zentiva, A. S. | Farmaceutická kompozice s obsahem úcinné látky atorvastatinu |
| KR20090128423A (ko) * | 2007-04-13 | 2009-12-15 | 니콕스 에스. 에이. | 아토르바스타틴 4-(니트록시)부틸 에스테르의 결정형 |
| US20110142883A1 (en) * | 2007-07-20 | 2011-06-16 | Actavis Group Ptc Ehf | Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts |
| WO2009024889A2 (fr) | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Composition pharmaceutique comprenant un inhibiteur de réductase hmg-coa et un ézétimibe |
| WO2009140341A2 (fr) * | 2008-05-13 | 2009-11-19 | Dr. Reddy's Laboratories Ltd. | Compositions d'atorvastatine |
| US20110082071A1 (en) * | 2008-05-15 | 2011-04-07 | Amal Elabbadi | Delivery system for an active ingredient |
| EP2127628A1 (fr) | 2008-05-27 | 2009-12-02 | Ranbaxy Laboratories Limited | Emballage de dose d'unité |
| US20110206770A1 (en) * | 2008-07-25 | 2011-08-25 | Alphapharm Pty. Ltd. | Atovaquone with a particle size diameter range (d90) of greater than 3 microns to about 10 microns |
| WO2010036600A1 (fr) * | 2008-09-24 | 2010-04-01 | Merck Sharp & Dohme Corp. | Compositions pharmaceutiques d’atorvastatine |
| US20100151034A1 (en) * | 2008-09-30 | 2010-06-17 | Astellas Pharma Inc. | Granular pharmaceutical composition of atorvastatin for oral administration |
| CN101791297B (zh) * | 2010-02-10 | 2012-03-28 | 中国药科大学 | 阿托伐他汀钙口崩片及其制备方法 |
| JP5534004B2 (ja) * | 2010-03-29 | 2014-06-25 | アステラス製薬株式会社 | 口腔内崩壊錠 |
| WO2011121823A1 (fr) * | 2010-03-29 | 2011-10-06 | アステラス製薬株式会社 | Composition pharmaceutique particulaire pour administration orale |
| US8372877B2 (en) * | 2010-04-16 | 2013-02-12 | Cumberland Pharmaceuticals | Stabilized statin formulations |
| WO2011139256A2 (fr) * | 2010-05-04 | 2011-11-10 | Bilgic Mahmut | Formulations stables de rosuvastatine |
| HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
| WO2011154009A1 (fr) * | 2010-06-10 | 2011-12-15 | Lifecycle Pharma A/S | Composition comprenant un principe actif sous une forme amorphe et une substance poreuse adsorbante |
| US20120165386A1 (en) * | 2010-12-27 | 2012-06-28 | Ranbaxy Laboratories Limited | Stable oral pharmaceutial composition of atorvastatin |
| RU2014124118A (ru) | 2011-11-15 | 2015-12-27 | Др. Редди'С Лабораторис Лтд. | Фармацевтические препараты, включающие аторвастатин и глимепирид |
| CN104069502B (zh) * | 2013-03-29 | 2018-02-16 | 北京罗诺强施医药技术研发中心有限公司 | 复合骨架材料及其药物组合物 |
| JP6507808B2 (ja) * | 2015-04-09 | 2019-05-08 | ニプロ株式会社 | 口腔内崩壊錠 |
| US20200261365A1 (en) | 2015-12-16 | 2020-08-20 | Merck Sharp & Dohme Corp. | Process for preparing pharmaceutical compositions |
| EP3184103A1 (fr) | 2015-12-21 | 2017-06-28 | Hexal AG | Composition pharmaceutique comprenant de l'atorvastatine ou un sel de celui-ci |
| CN106420645A (zh) * | 2016-11-24 | 2017-02-22 | 浙江新东港药业股份有限公司 | 一种含阿托伐他汀钙片及制备方法 |
| CN108421045B (zh) * | 2018-04-02 | 2021-09-24 | 北京海晶生物医药科技有限公司 | 一种阿托伐他汀钙组合物、制剂及其制备方法 |
| CN109044989A (zh) * | 2018-10-09 | 2018-12-21 | 河南师范大学 | 一种阿托伐他汀钙胶囊制剂及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
| DK0680320T3 (da) * | 1993-01-19 | 1999-10-25 | Warner Lambert Co | Stabilt oralt CI-981-præparat og fremgangsmåde til fremstilling deraf |
| SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
| US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
-
2003
- 2003-02-14 KR KR10-2004-7012657A patent/KR20040101229A/ko not_active Application Discontinuation
- 2003-02-14 AR ARP030100494A patent/AR038839A1/es not_active Application Discontinuation
- 2003-02-14 PE PE2003000161A patent/PE20030935A1/es not_active Application Discontinuation
- 2003-02-14 PL PL03371337A patent/PL371337A1/xx not_active Application Discontinuation
- 2003-02-14 IL IL16355003A patent/IL163550A0/xx unknown
- 2003-02-14 MX MXPA04007905A patent/MXPA04007905A/es not_active Application Discontinuation
- 2003-02-14 WO PCT/IB2003/000505 patent/WO2003068191A1/fr active Application Filing
- 2003-02-14 CA CA002475722A patent/CA2475722A1/fr not_active Abandoned
- 2003-02-14 US US10/367,552 patent/US20030175338A1/en not_active Abandoned
- 2003-02-14 AU AU2003245736A patent/AU2003245736A1/en not_active Abandoned
- 2003-02-14 JP JP2003567375A patent/JP2005522444A/ja active Pending
- 2003-02-14 BR BR0307720-9A patent/BR0307720A/pt not_active IP Right Cessation
- 2003-02-14 OA OA1200400219A patent/OA12777A/en unknown
- 2003-02-14 AP APAP/P/2004/003112A patent/AP2004003112A0/en unknown
- 2003-02-14 CN CNA038070286A patent/CN1642526A/zh active Pending
- 2003-02-14 EP EP03405088A patent/EP1336405A1/fr not_active Withdrawn
- 2003-02-14 EA EA200401059A patent/EA200401059A1/ru unknown
-
2004
- 2004-08-13 IS IS7404A patent/IS7404A/is unknown
- 2004-08-13 CO CO04079402A patent/CO5600997A2/es not_active Application Discontinuation
- 2004-08-16 EC EC2004005235A patent/ECSP045235A/es unknown
- 2004-09-01 ZA ZA200406970A patent/ZA200406970B/en unknown
- 2004-09-09 NO NO20043790A patent/NO20043790L/no unknown
- 2004-09-13 HR HR20040829A patent/HRP20040829A2/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1336405A1 (fr) | 2003-08-20 |
| CA2475722A1 (fr) | 2003-08-21 |
| ECSP045235A (es) | 2004-09-28 |
| KR20040101229A (ko) | 2004-12-02 |
| BR0307720A (pt) | 2005-01-25 |
| AP2004003112A0 (en) | 2004-09-30 |
| JP2005522444A (ja) | 2005-07-28 |
| US20030175338A1 (en) | 2003-09-18 |
| EA200401059A1 (ru) | 2005-02-24 |
| ZA200406970B (en) | 2005-06-20 |
| OA12777A (en) | 2006-07-06 |
| HRP20040829A2 (en) | 2006-07-31 |
| WO2003068191A1 (fr) | 2003-08-21 |
| CO5600997A2 (es) | 2006-01-31 |
| AR038839A1 (es) | 2005-01-26 |
| MXPA04007905A (es) | 2004-11-26 |
| PE20030935A1 (es) | 2003-10-30 |
| PL371337A1 (en) | 2005-06-13 |
| AU2003245736A1 (en) | 2003-09-04 |
| IS7404A (is) | 2004-08-13 |
| NO20043790L (no) | 2004-11-08 |
| CN1642526A (zh) | 2005-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL163550A0 (en) | Formulations of atorvastatin stabilized with alkali metal additions | |
| IL208892A0 (en) | Use of hmg fragment as anti-inflammatory agents | |
| IL162404A0 (en) | Stabilized formulations of adenovirus | |
| PL369102A1 (en) | Set of teeth | |
| IL166591A0 (en) | Preparation of aztreonam | |
| AU2003302372A8 (en) | Formulations of finasteride | |
| AU2003275505A1 (en) | Electowinning of metals | |
| IL161178A0 (en) | MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES | |
| AU2003298725A8 (en) | Preparation of metallotexaphyrins | |
| TW493498U (en) | Structure improvement of screwdriver | |
| AU2002360974A1 (en) | Novel use of alloys | |
| GB0127320D0 (en) | Reduction of elecromagnetic radiation | |
| TW493722U (en) | Improved structure of lampwick | |
| TW484490U (en) | Structural improvement of multiple-functional wrench | |
| HU0104370D0 (en) | Honeyed schnaps of oerseg | |
| IL165356A0 (en) | Preparation of 4-haloalkylkylnicotinamides | |
| PL356853A1 (en) | Application of bacteriphages | |
| TW545172U (en) | Improved structure of thermostatic barrel | |
| TW497714U (en) | Structure improvement of electric-sensing target | |
| TW557066U (en) | Structure of luminance compensation design | |
| TW554950U (en) | Improved structure of bumping structure | |
| GB0129049D0 (en) | Improvements to self-sterilisation of surfaces | |
| TW501859U (en) | Improvement of fixing-stand structure | |
| TW506543U (en) | Structure of object camera | |
| TW533774U (en) | Structure improvement of flyswatter |